Review Article

You have full text access to this OnlineOpen article

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer

  1. Guru Sonpavde MD1,2,†,‡,*,
  2. Kim N. Chi MD3,§,
  3. Thomas Powles MRCP4,¶,
  4. Christopher J. Sweeney MD5,
  5. Noah Hahn MD5,
  6. Thomas E. Hutson DO, PharmD1,‖,
  7. Matthew D. Galsky MD1,††,
  8. William R. Berry MD1,‡‡,
  9. Dov Kadmon MD2

Article first published online: 16 OCT 2007

DOI: 10.1002/cncr.23085

Issue

Cancer

Cancer

Volume 110, Issue 12, pages 2628–2639, 15 December 2007

Additional Information

How to Cite

Sonpavde, G., Chi, K. N., Powles, T., Sweeney, C. J., Hahn, N., Hutson, T. E., Galsky, M. D., Berry, W. R. and Kadmon, D. (2007), Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer, 110: 2628–2639. doi: 10.1002/cncr.23085

Author Information

  1. 1

    Genitourinary Oncology Program, U.S. Oncology Research, Houston, Texas

  2. 2

    Scott Department of Urology, Baylor College of Medicine, Houston, Texas

  3. 3

    British Columbia Cancer Agency, Vancouver Cancer Center, Vancouver, British Columbia, Canada

  4. 4

    Department of Oncology, London Hospital, London, United Kingdom

  5. 5

    Department of Medicine, Section of Medical Oncology, Indiana University Medical Center, Indianapolis, Indiana

  1. †

    Dr. Sonpavde has acted as a member of the Speakers' Bureau for Sanofi-Aventis, Pfizer, and Novartis and has received research support from Pfizer, Eli Lilly, AstraZeneca, BMS, and Cytogen.

  2. ‡

    Fax: (281) 332–8429

  3. §

    Dr. Chi has received research support from Sanofi-Aventis, Pfizer, Wyeth, and Abbott.

  4. Dr. Powles has received research support from GlaxoSmithKline.

  5. ‖

    Dr. Hutson receives research support from Bayer/Onyx, Pfizer, and GlaxoSmithKline. He is also a member of the Advisory Board/consultant for Bayer/Onyx, Pfizer, Dendreon, and Sanofi-Aventis and is a member of the Speakers' Bureau for Bayer/Onyx, Pfizer, Amgen, Sanofi-Aventis, and Genentech.

  6. ††

    Dr. Galsky is a member of the Speakers' Bureau for Pfizer.

  7. ‡‡

    Dr. Berry is a member of the Speakers' Bureau for Sanofi-Aventis.

*Genitourinary Oncology Program, U.S. Oncology Research, Department of Medicine and Urology, Baylor College of Medicine, 501 Medical Center Boulevard, Webster, TX 77598

  1. †

    Dr. Sonpavde has acted as a member of the Speakers' Bureau for Sanofi-Aventis, Pfizer, and Novartis and has received research support from Pfizer, Eli Lilly, AstraZeneca, BMS, and Cytogen.

  2. ‡

    Fax: (281) 332–8429

  3. §

    Dr. Chi has received research support from Sanofi-Aventis, Pfizer, Wyeth, and Abbott.

  4. Dr. Powles has received research support from GlaxoSmithKline.

  5. ‖

    Dr. Hutson receives research support from Bayer/Onyx, Pfizer, and GlaxoSmithKline. He is also a member of the Advisory Board/consultant for Bayer/Onyx, Pfizer, Dendreon, and Sanofi-Aventis and is a member of the Speakers' Bureau for Bayer/Onyx, Pfizer, Amgen, Sanofi-Aventis, and Genentech.

  6. ††

    Dr. Galsky is a member of the Speakers' Bureau for Pfizer.

  7. ‡‡

    Dr. Berry is a member of the Speakers' Bureau for Sanofi-Aventis.

Publication History

  1. Issue published online: 3 DEC 2007
  2. Article first published online: 16 OCT 2007
  3. Manuscript Accepted: 12 JUL 2007
  4. Manuscript Revised: 5 JUL 2007
  5. Manuscript Received: 14 MAY 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (134K)

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43–66.
    Direct Link:
  • 2
    Bolla M,Collette L,Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360: 103–106.
  • 3
    Messing EM,Manola J,Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341: 1781–1788.
  • 4
    Gomella LG. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int. 2007; 99(suppl 1): 25–29.
    Direct Link:
  • 5
    Lu-Yao G,Moore DF,Oleynick JU, et al. Population based study of hormonal therapy and survival in men with metastatic prostate cancer. J Urol. 2007; 177: 535–539.
  • 6
    Smith MR,Kabbinavar F,Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005; 23: 2918–2925.
  • 7
    Tannock IF,de Wit R,Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502–1512.
  • 8
    Petrylak DP,Tangen CM,Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513–1520.
  • 9
    Grossman HB,Natale RB,Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859–866Erratum in N Engl J Med. 2003;349:1880.
  • 10
    Bazinet M,Zheng W,Begin LR, et al. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology. 1997; 49: 721–725.
  • 11
    Kattan MW,Eastham JA,Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 766–771.
  • 12
    Greene KL,Meng MV,Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CAPSURE). J Urol. 2004; 171(6 pt 1): 2255–2259.
  • 13
    Kattan MW,Shariat SF,Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003; 21: 3573–3579.
  • 14
    Soloway MS,Sharifi R,Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2b:NxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995; 154: 424–428.
  • 15
    Schulman CC,Debruyne FM,Forster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2–3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000; 38: 706–713.
  • 16
    Aus G,Abrahamsson PA,Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002; 90: 561–566.
    Direct Link:
  • 17
    Meyer F,Moore L,Bairati I, et al. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol. 1999; 162: 2024–2028.
  • 18
    Gleave ME,Goldenberg SL,Jones EC, et al. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Semin Urol Oncol. 1996; 14(suppl 2): 39–47.
  • 19
    Gleave ME,Goldenberg SL,Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001; 166: 500–506.
  • 20
    Selli C,Montironi R,Bono A, et al; PROSIT Study Group. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol. 2002; 55: 508–513.
  • 21
    Mostaghel EA,Coleman IM,Coleman R, et al. Prostate gene expression changes after neoadjuvant 5α-reductase inhibition: identification of potential chemopreventive mechanisms. 2007 Prostate Cancer Symposium, Orlando, Florida, February 22–24, 2007. Abstract 1.
  • 22
    Eigl BJC,Eggener SE,Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005; 11: 4905–4911.
  • 23
    Tang Y,Khan MA,Goloubeva O, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res. 2006; 12: 169–174.
  • 24
    Pettaway CA,Pisters LL,Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol. 2000; 18: 1050–1057.
  • 25
    Konety BR,Eastham JA,Reuter VE, et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol. 2004; 171(2 pt 1): 709–713.
  • 26
    Winquist JE,Chi KN,Chin J, et al. Multicenter phase II study of combined docetaxel and neoadjuvant hormone therapy (NHT) prior to prostatectomy for patients with high risk localized prostate cancer: pathologic outcomes and 3-year follow-up analyses. J Clin Oncol ASCO Annu Meeting Proc. 2007; 25: 18S. Abstract 5002.
  • 27
    Fossa SD,Fossa J,Aakvaag A. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate. J Urol. 1977; 118: 1013–1018.
  • 28
    Van Poppel H,De Ridder D,Elgamal AA, et al., and the Belgian Uro-Oncological Study Group. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol. 1995; 154: 429–434.
  • 29
    Hussain M,Smith DC,El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/ locally advanced prostate cancer. Urology. 2003; 61: 774–780.
  • 30
    Clark PE,Peereboom DM,Dreicer R, et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001; 57: 281–285.
  • 31
    Dreicer R,Magi-Galluzzi C,Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004; 63: 1138–1142.
  • 32
    Febbo PG,Richie JP,George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005; 11: 5233–5240.
  • 33
    Garzotto M,Myrthue A,Higano CS,Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol. 2006; 24: 254–259.
  • 34
    Friedman JD,Vaishampayan U,Wood D, et al. Neoadjuvant docetaxel and capecitabine in patients with high risk/locally advanced prostate cancer: final results of a phase II study. J Clin Oncol ASCO Annu Meeting Proc. 2007; 23: 18S. Abstract 5147.
  • 35
    Vuky J,Porter C,Isacson C, et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. 2006 Multidisciplinary Prostate Cancer Symposium, San Francisco, California, February 24–26, 2006. Abstract 80.
  • 36
    Febbo PG,Thorner A,Rubin MA, et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006; 12: 152–158.
  • 37
    Carducci MA,Musib L,Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006; 24: 4092–4099.
  • 38
    Sachdev D,Singh R,Fujita-Yamaguchi Y,Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-IGF therapy in cancer. Cancer Res. 2006; 66: 2391–2402.
  • 39
    Dreicer R,Klein EA,Elson P, et al. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol. 2005; 23: 82–86.
  • 40
    Garcia JA,Magi-Galluzzi C,Rothaermel J, et al. Neoadjuvant GM-CSF and thalidomide in men with high-risk prostate carcinoma undergoing radical prostatectomy. J Clin Oncol 2006 ASCO Annu Meeting Proc. 2006; 24(pt 1, June 20 suppl): 18S. Abstract 4564.
  • 41
    George DJ,Halabi S,Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001; 7: 1932–1936.
  • 42
    Shariat SF,Anwuri VA,Lamb DJ, et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004; 22: 1655–1663.
  • 43
    Motzer RJ,Hutson TE,Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115–124.
  • 44
    Demetri GD,van Oosterom AT,Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet. 2006; 14:368: 1329–1338.
  • 45
    Efstathiou E,Tronsoco P,Wen S, et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007; 13: 1224–1231.
  • 46
    Papandreou CN,Daliani DD,Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 2108–2121.
  • 47
    Hedlund TE,van Bokhoven A,Johannes WU, et al. Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro. Prostate. 2006; 66: 557–566.
    Direct Link:
  • 48
    Marrocco DL,Tilley WD,Bianco-Miotto T, et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007; 6: 51–60.
  • 49
    Chi KN,Eisenhauer E,Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005; 97: 1287–1296.
  • 50
    Kucuk O,Sarkar FH,Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2001; 10: 861–868.
  • 51
    Sooriakumaran P,Macanas-Pirard P,Coley H, et al. A blinded, randomized controlled neo-adjuvant trial of celecoxib in patients with localized prostate cancer. 2007 Prostate Cancer Symposium, Orlando, Florida, February 22–24, 2007. Abstract 50.
  • 52
    Pisters L,Pettaway C,Troncoso P, et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004; 10: 2587–2593.
  • 53
    Trudel S,Trachtenberg J,Toi A, et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high risk localized prostate cancer. Cancer Gene Ther. 2003; 10: 755–763.
  • 54
    Belldegrun A,Tso CL,Zisman A, et al. Interleukin-2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther. 2001; 12: 883–892.
  • 55
    Mohsin SK,Weiss HL,Gutierrez MC, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005; 23: 2460–2468.
  • 56
    Eilber FC,Rosen G,Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001; 19: 3203–3209.
  • 57
    Meric F,Hess KR,Varma DG, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002; 95: 1120–1126.
    Direct Link:
View Full Article (HTML) Get PDF (134K)